Long The High Risk Psilocybin Mushroom Therapy Secular Bull RunNot looking for an immediate turn around because Macro-Market conditions and retail risk tolerance is severely negative right now. However, this sector has huge potential to be a bullish meme in years ahead. Think of getting into Pot Stocks 2.0 before the moon pumps
In 2018–19, the United States Food and Drug Administration (FDA) granted breakthrough therapy designation to facilitate further research for psilocybin in the possible treatment of depressive disorders. As of 2020, research on the use of psilocybin indicated it caused hallucinations with inability to establish reality from fantasy, panic reactions, and possible psychoses at high doses.
In November 2020, the U.S. state of Oregon legalized psilocybin for people age 21 and older, and decriminalized possession or use of psilocybin mushrooms for medical conditions, such as depression, anxiety, or PTSD.
